Globe Newswire (Thu, 16-Jul 11:41 AM ET)
Business Wire (Mon, 13-Jul 1:30 PM ET)
Globe Newswire (Mon, 6-Jul 2:02 PM ET)
Are NUVL, ROKU, PAYO, HUN Obtaining Fair Deals for their Shareholders?
PRNewswire (Thu, 2-Jul 3:37 PM ET)
Globe Newswire (Thu, 2-Jul 5:08 AM ET)
Globe Newswire (Tue, 30-Jun 2:50 PM ET)
Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders?
PRNewswire (Thu, 25-Jun 1:57 PM ET)
Are ROKU, SLP, NUVL, DAN Obtaining Fair Deals for their Shareholders?
PRNewswire (Mon, 22-Jun 5:07 PM ET)
Globe Newswire (Fri, 19-Jun 9:27 AM ET)
Are NUVL, DAN, PAYO Obtaining Fair Deals for their Shareholders?
PRNewswire (Thu, 18-Jun 11:28 AM ET)
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Nuvalent - Class A trades on the NASDAQ stock market under the symbol NUVL.
As of July 17, 2026, NUVL stock price was flat at $123.96 with million shares trading.
NUVL has a beta of 0.95, meaning it tends to be less sensitive to market movements. NUVL has a correlation of 0.06 to the broad based SPY ETF.
NUVL has a market cap of $9.81 billion. This is considered a Mid Cap stock.
In the last 3 years, NUVL traded as high as $123.99 and as low as $39.86.
The top ETF exchange traded funds that NUVL belongs to (by Net Assets): VTI, VB, VBR, VXF, VTWO.
NUVL has outperformed the market in the last year with a price return of +44.7% while the SPY ETF gained +19.5%. NUVL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +15.2% and +0.2%, respectively, while the SPY returned +4.9% and -0.2%, respectively.
NUVL support price is $123.88 and resistance is $124.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NUVL shares will trade within this expected range on the day.
